Tetany: Possible adverse effect of bevacizumab

Indian Journal of Cancer

Volumn 48, Issue 1, 2011, Pages 31-33

  Anwikar, S R ^a   Bandekar, M S ^a   Patel, T K ^b   Patel, P B ^b   Kshirsagar, N A ^a  

^a MAHARASHTRA UNIVERSITY OF HEALTH SCIENCES   (India)

^b GOVERNMENT MEDICAL COLLEGE   (India)

Author keywords

adverse effect; Bevacizumab; serum calcium; tetany

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; CLEMASTINE; DEXAMETHASONE; DIAZEPAM; DIPYRONE; DOCETAXEL; EPIRUBICIN; ERLOTINIB; ONDANSETRON; OXALIPLATIN; OXAZEPAM; TRAMADOL; VASCULOTROPIN;

ARTICLE; CALCIUM METABOLISM; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CANCER; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; MUSCLE CRAMP; MUSCLE HYPERTONIA; MUSCLE SPASM; MUSCULOSKELETAL STIFFNESS; OSTEOCLAST; OSTEOLYSIS; SWEDEN; TETANY; TRISMUS;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; SURVIVAL RATE; SWEDEN; TETANY; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79951994495     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.75819     Document Type: Article

References (19)

1. Bruder JM, Guise TA, Mundy GR. Mineral metabolism. Endocrine and metabolism. 4th ed. New York McGraw - Hill companies; 2001. p. 1079-177.
2. Bringhurst FR, Demay MB, Kronenberg HM. Hormons and disorders of mineral metabolism. Williams textbook of endocrinology. 10th ed. USA: Elsevier Science; 2003. p. 1303-73.
3. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (avstin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333:328-35. (Pubitemid 40848295)
4. Chabner BA, Amrein PC, Druker BJ. Antineoplastic Agents. Goodman and Gilman's the Pharmacologiucal Basis of Therapeutics. 11th ed. New York: McGraw-Hill, Medical Publishing Division; 2006. p. 1315-404.
5. Takimoto CH, Remick SC, Sharma S. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: A national cancer institute organ dysfunction working group study. J Clin Oncol 2003;21:2664-72. (Pubitemid 46606309)
6. Docetaxel IV. Available from: http://www.medscape.com/druginfo/dosage? drugid=4890anddrugname=Docetaxel+IV [last cited on 2009 Jan].
7. Clemastine Oral. Available from: http://www.medscape.com/druginfo/dosage? drugid=7141anddrugname=Clemastine+Oral [last cited on 2009 Jan].
8. Tramadol (Tramadol Hydrochloride) - side effects and adverse reactions. Available from: http://www.druglib.com/druginfo/tramadol/side-effects/ [last cited on 2009 Jan].
9. Gutstein HB, Akil H. Opoid analgesics. Goodman and Gilman's The Pharmacologiucal Basis of Therapeutics. 11th ed. New York: McGraw-Hill, Medical Publishing Division; 2006. p. 547-90.
10. Henriksen K, Karsdal M, Delaisse JM, Engsig MT. RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1/2-dependent mechanism. J Biol Chem 2003;278:48745-53. (Pubitemid 41079516)
11. Yang Q, McHugh KP, Patntirapong S. VEGF enhancement of osteoclast survival and bone resorption involves VEGF receptor-2 signaling and beta3-integrin. Matrix Biol 2008;27:589-99.
12. Kuku M, Kohno S, Kuwata T. Effects of vascular endothelial growth factor on osteoclast induction during tooth movement in mice. J Dent Res 2001;80:1880-3. (Pubitemid 33038054)
13. Gerber HP, Vu TH, Ryan AM. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999;5:623-8. (Pubitemid 29289424)
14. Esbrit P, Victoria M, Miguel F. Terminal parathyroid hormone-related protein increases vascular endothelial growth factor in human osteoblastic cells. J Am Soc Nephrol 2000;11:1085-92. (Pubitemid 30367938)
15. Nakagawa M, Kaneda T, Arakawa T, Morita S, Sato T, Yomada T, et al. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 2000;473:161-4. (Pubitemid 30254282)
16. Niida S, Kondo T, Hiratsuka S, Hayashi S, Amizuka N, Noda T, et al. VEGF receptor 1 signaling is essential for osteoclast development and bone marrow formation in colony-stimulating factor 1-deficient mice. Proc Natl Acad Sci U S A 2005;102:14016-21. (Pubitemid 41377695)
17. Cooney MM, Garcia J, Brell J. A phase I study of bevacizumab in combination with sunitinib in advanced solid tumors. J Clin Oncol 2007;18:15532.
18. Bevacizumab IV: Dosage, Uses and Warnings. Available from: http//:www.medscape.com [last cited on 2009 Jan].
19. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: Bevacizumab (Avastin®) plus carboplatin and paclitaxel as first-line treatment of advanced metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007;12:713-8. (Pubitemid 47036205)